News

Click here to answer this week's HS poll.

The 2023 Society for Pediatric Dermatology Meeting kicks off in Asheville, North Carolina, on July 13.

Boehringer Ingelheim announced that novel antibody treatment can interfere in the IL-36 signaling pathway, reducing flares.

Bush revealed what she is looking forward to in the coming year and the goals she wants to accomplish.

Dupilumab self-injection has been available to patients in Japan since May 2019.

Compared to patients without melasma, blue light irradiation caused minimal changes in patients with melasma.

Click here to answer this week's poll.

Examining the genes and signaling pathways of development of atopic dermatitis and tooth agenesis reveals possible link between the two diseases.

In a clinical trial, patients reported improved quality of life after 12 weeks on sonelokimab.

Findings indicate no rebound effect when participants discontinue dupilumab.

Steven Hacker, MD, explains how the electromagnetic resonant scalpel provides a digitized record of the in vivo scalpel path.

ICYMI, this week we had stories about burn management and treatment in light of the July 4 holiday, pearls from the 2023 World Congress of Dermatology meeting in Singapore, acral lentiginous melanoma in AAPI patients, and more.

Bunick presented 3 sessions at the 2023 World Congress of Dermatology meeting in Singapore.

Data presented in a poster presentation at the 2023 World Congress of Dermatology meeting in Singapore showed significant improvements to patient quality of life.

Pediococcus acidilactici demonstrated significant clinical efficacy and potential in treating hyperpigmentation.

The HEROES program wants to make it easier for stylists to recognize scalp conditions and advise their clients to seek medical help.

The study found that using the multi-peptide eye serum twice a day resulted in improved elasticity and firmness.

As the 25th World Congress of Dermatology winds down this week, Chovatiya shares highlights from his sessions in Singapore.

A poster presentation from the 19th Annual Skin of Color Society Scientific Symposium analyzed the differences in presentation of cutaneous melanoma among Asian American and Pacific Islander patients.

Aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light achieves positive results in treating squamous cell carcinoma.

Janssen Pharmaceutical Companies announced its oral treatment for moderate to severe plaque psoriasis will be taken to Phase 3 clinical trials.

Pediatric patients with moderate to severe eczema demonstrated an increased risk of experiencing the food allergy.

As we have surpassed the halfway mark of 2023, Dermatology Times is spotlighting vitiligo coverage and news from the first half of year.

The American Acne and Rosacea Society brings attention to the negative emotional effects of acne.

New pharmacokinetic phase 3 data will be presented at the 2023 Society for Pediatric Dermatology meeting next week.

The authorization comes just over 2 months after the drug’s approval in the European Union.

Investigators reported that deucravacitnib improved quality of life and clinical outcomes scores in those with moderate to severe psoriasis.

Trained immunity may act as an enhancer and continuous trigger in the disease’s pathogenesis.

In this week’s Pointers With Portela, the 208SkinDoc interviews Ron Robinson, a well-known cosmetic chemist in the skin care industry.